Home > Back to Publisher > Report Information

Cancer Vaccines Markets

TriMark Publications
May 1, 2011
114 Pages - SKU: TRI6276725

Abstract Table of Contents Related Reports

Cancer vaccines have the potential to become a significant force in future cancer treatments. In 2010, Dendreon's Provenge became the first cancer vaccine approved by the FDA, generating renewed interest and support for this type of cancer immune therapy. Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. This relatively new commercial market for cancer vaccines is poised to dramatically increase to over $7 billion by 2015. The purpose of this TriMark Publications report is to supply comprehensive information on the developing market for cancer vaccines.

This study surveys almost all of the companies known to be marketing, manufacturing, or developing cancer vaccines in the world, providing in-depth analysis of the current and emerging technologies in the cancer vaccines market. Each company is extensively examined, with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Moreover, this report provides detailed discussions of cancer vaccines funding trends, intellectual property, market opportunities, research collaborations, partnership activities, regulatory issues and guidelines for establishing new ventures. Detailed tables and charts with sales forecasts and market share data are also included.

Additional Information

Press Release

Cancer Vaccines Market Forecasted to Catapult to Over $7 Billion by 2015

New York, NY, April 11, 2011 - TriMarkPublications.com cites in its newly published “Cancer Vaccines Markets” report that the cancer vaccines market will catapult to over $7 billion by 2015.

Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. The FDA’s first approval of a therapeutic cancer vaccine in 2010 has demonstrated the potential for these novel types of treatments to successfully enter a major market. The cancer vaccines market is driven by the potential for cancer vaccines to be used with existing cancer therapeutics, their possibility of being used as long-term treatments, and their status as niche products fulfilling unmet therapeutic needs.

The “Cancer Vaccines Markets” report covers:

Antigen/Adjuvant Vaccines
DNA Vaccines
Prophylactic Vaccines
Therapeutic Vaccines
Tumor Cell Vaccines
Dendritic Cell (DC) Vaccines
Anti-Idiotype Vaccines
Cervical Cancer (HPV)
Breast Cancer
Screening and Cancer Detection
Immune Response
Personalized Medicine
Combination Therapies
Pharmaceutical Product Regulation
New Drug Application (NDA)
Biologics License Application (BLA)
Oncology Biomarker Qualification Initiative

The “Cancer Vaccines Markets” report examines companies manufacturing cancer vaccines equipment and supplies in the world. Companies covered include: Advaxis, Agenus (formerly Antigenics), Alphavax, Antigen Express, Apthera, Argos, AVAX, Bavarian Nordic, Bellicum, BioSante, Biovest, Celldex, CG, CureVac, DanDrit, Dendreon, EMD Serono, Geron, Glaxosmithkline, Globeimmune, Immatics, ImmunoCellular, Immunovaccine, Inovio, KAEL-Gemvax, MannKind, Mologen, NewLink Genetics, Northwest, NovaRx, Oxford BioMedica, Prima BioMed, Scancell, Transgene, Trimed, Vaccinogen and Vical.

1. Overview: 1.1 About this Report; 1.2 Scope of the Report; 1.3 Objectives; 1.4 Methodology; 1.5 Executive Summary
2. Overview of Cancer: 2.1 Cancer Statistics; 2.2 The Cost of Cancer; 2.3 Cancers Being Targeted by Vaccine Therapies: Overview of Disease and Market
3. Introduction to Cancer Vaccines: 3.1 Overview of the Types of Cancer Vaccines; 3.2 Antigen/Adjuvant Vaccines; 3.3 DNA Vaccines; 3.4 Vector-based Vaccines; 3.5 Tumor Cell Vaccines; 3.6 Dendritic Cell (DC) Vaccines; 3.7 Anti-Idiotype Vaccines
4. Prophylactic Vaccines on the Market and in Development: 4.1 Cervical Cancer (HPV); 4.2 Prophylactic Breast Cancer Vaccine in Development
5. Therapeutic Vaccines on the Market and in Development: 5.1 Breakthroughs in the Cancer Vaccine Market: Vaccines on the Market; 5.2 Vaccines in Development (by Type of Vaccine)
6. Challenges and Issues in Cancer Vaccine Development: 6.1 Eliciting Appropriate Immune Response Against Cancer; 6.2 Clinical Trial Design; 6.3 Combination Therapies
7. Regulatory Issues: 7.1 Pharmaceutical Product Regulation; 7.2 New Drug Application (NDA) or Biologics License Application (BLA); 7.3 Post-Approval Phase; 7.4 Fast-Track Review; 7.5 Orphan Drug Designation and Exclusivity; 7.6 What Regulatory Guidance Is Needed for Companion Biomarkers?; 7.7 Oncology Biomarker Qualification Initiative; 7.8 IRB Approval in Clinical Trials; 7.9 U.S. Patent and Trademark Office (USPTO)
8. Trends Affecting the Cancer Vaccine Market: 8.1 Screening and Cancer Detection; 8.2 Public Perception of Vaccines; 8.3 Insurance Issues; 8.4 New Technological and Scientific Developments; 8.5 Personalized Medicine; 9. Business Landscape; 9.1 Technology and Market Trends; 9.2 M&A Activity; 9.3 Partnering; 9.4 Competitive Situation; 9.5 Intellectual Property Rights 97; 9.6 Industry Challenges and Strategic Recommendations for Commercialization; 9.7 Opportunities and Strategic Recommendations; 9.8 Requirements for a Successful Cancer Vaccine Products Industry
10. Company Profiles: 10.1 Advaxis; 10.2 Agenus (formerly Antigenics); 10.3 AlphaVax; 10.4 Antigen Express; 10.5 Apthera; 10.6 Argos Therapeutics; 10.7 AVAX Technologies; 10.8 Bavarian Nordic; 10.9 Bellicum Pharmaceuticals; 10.10 BioSante Pharmaceuticals; 10.11 Biovest International; 10.12 Celldex Therapeutics; 10.13 CG Therapeutics; 10.14 CureVac; 10.15 DanDrit Biotech; 10.16 Dendreon; 10.17 EMD Serono; 10.18 Geron; 10.19 GlaxoSmithKline; 10.20 GlobeImmune; 10.21 Immatics Biotechnologies; 10.22 ImmunoCellular Therapeutics; 10.23 Immunovaccine; 10.24 Inovio Pharmaceuticals; 10.25 KAEL-Gemvax; 10.26 MannKind; 10.27 Mologen AG; 10.28 NewLink Genetics Corporation; 10.29 Northwest Biotherapeutics; 10.30 NovaRx; 10.31 Oxford BioMedica; 10.32 Prima BioMed; 10.33 Scancell; 10.34 Transgene; 10.35 Trimed Biotech; 10.36 Vaccinogen; 10.37 Vical
INDEX OF FIGURES: Figure 2.1: Estimates of National Expenditures for Cancer Care in 2006 by Cancer Site; Figure 2.2: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Male, 2006; Figure 2.3: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Female, 2006; Figure 3.1: Antigen Presentation; Figure 3.2: Antigen/Adjuvant Cancer Vaccine Immunotherapy Process; Figure 3.3: DNA Cancer Vaccine Immunotherapy Process; Figure 3.4: Viral Vector Cancer Vaccine Immunotherapy Process; Figure 3.5: Modified Tumor Cell Cancer Vaccines; Figure 3.6: Dendritic Cell Vaccination Process; Figure 3.7: Schematic of Anti-idiotype Antibodies for Cancer Vaccines; Figure 5.1: New Therapeutic Cancer Vaccines Entering Clinical Study Per Year During 1990-2006
INDEX OF TABLES: Table 2.1: Estimated New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 2010; Table 2.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S. in 2010, by Sex; Table 2.3: Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 2008; Table 2.4: Number of New Cancer Cases and Deaths by World Area, 2008; Table 2.5: Estimated Annual Costs of Cancer in the U.S. in Billions, 2008; Table 2.6: Cancer Vaccines in the Pipeline, by Cancer Type; Table 3.1: Infectious Agents Involved in Cancer; Table 3.2: Cancer Vaccine Technologies; Table 3.3: Antigens Commonly Found in Cancer Vaccines; Table 3.4: Adjuvants Commonly Found in Cancer Vaccines; Table 4.1: Cervical Cancer Vaccines on the Market; Table 5.1: Therapeutic Vaccines on the Market; Table 5.2: Pipeline of Therapeutic Cancer Vaccines, by Type of Vaccine; Table 5.3: Antigen/Adjuvant Vaccines in Development; Table 5.4: DNA and RNA Vaccines in Development; Table 5.5: Vector-based Vaccines in Development; Table 5.6: Autologous Tumor Cell Vaccines in Development; Table 5.7: Allogeneic Tumor Cell Vaccines in Development; Table 5.8: Dendritic Cell Vaccines in Development; Table 5.9: Anti-Idiotype Vaccines in Development; Table 5.10: Competitors with Phase III Cancer Vaccine Candidates in Their Pipelines; Table 6.1: Mechanisms of Immune Evasion by Cancers; Table 6.2: Key Recommendations for Cancer Vaccine Clinical Trial Design; Table 6.3: Challenges and Strategic Recommendations for Clinical Trial Design; Table 6.4 Combination Strategies to Enhance a Vaccine's Anti-Tumor T-Cell Response; Table 7.1: Focus Areas for the FDA Critical Path Initiative; Table 9.1: Industry Challenges and Strategic Recommendations for Commercialization; Table 9.2: Required Elements of a Manufacturing Facility; Table 9.3: CMO Qualification Audit-Points to Investigate; Table 9.4: Strategies for Marketing Cancer Vaccines

Cancer Vaccines Markets

Share this report

Other tasks

Research Assistance

Related Markets

Cancer Vaccines Reports

Free Alert Me service